Partnering Opportunities

Partnering Overview

Targeting unique disease-specific peptide HLA complexes is anĀ essential input for filling immunotherapeutic drug discovery pipelines. Pure MHC’s Business Development plan makes it easy to partner with mutually favorable terms and creative flexibility to meet your specific corporate needs.

Available TCRm mAb

Cancer PathogenTargets
Breast HIV-1
Ovarian including Cisplatin Resistant WNV
AML Influenza*
“Melanoma, Prostate,
and other cancers”
RSV

Source Proteins (relative to multiple cancers)

Her2/neu Hcg-Ī² CD19 NY-ESO-1 hTERT
MAGE-1 MAGE-B2 CEA MIF p53
USP3 gp100 Tyrosinase PR1 p68


Contact Us
to learn more.